Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30606-9 ◽

2021 ◽

Vol 22 (2) ◽

pp. 190-197

Author(s):

B C John Cho ◽

Laura Donahoe ◽

Penelope A Bradbury ◽

Natasha Leighl ◽

Shaf Keshavjee ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Single Centre ◽

Download Full-text

Faculty Opinions recommendation of Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725915176.793512682 ◽

2015 ◽

Author(s):

Paul Van Schil

Keyword(s):

Neoadjuvant Chemotherapy ◽

Malignant Pleural Mesothelioma ◽

Extrapleural Pneumonectomy ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Multicentre Phase ◽

Download Full-text

Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial

Annals of Oncology ◽

10.1093/annonc/mdx440.074 ◽

2017 ◽

Vol 28 ◽

pp. v648 ◽

Author(s):

G. Zalcman ◽

J. Mazieres ◽

L. Greillier ◽

S. Lantuejoul ◽

P. Dô ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

A multicenter phase 2 trial of neo-adjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.7179 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 7179-7179 ◽

Author(s):

L. M. Krug ◽

H. I. Pass ◽

V. W. Rusch ◽

D. J. Sugarbaker ◽

K. E. Rosenweig ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Extrapleural Pneumonectomy ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase

Download Full-text

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

The Lancet Oncology ◽

10.1016/s1470-2045(20)30462-9 ◽

2020 ◽

Vol 21 (9) ◽

pp. 1213-1223 ◽

Author(s):

Anna K Nowak ◽

W Joost Lesterhuis ◽

Peey-Sei Kok ◽

Chris Brown ◽

Brett GM Hughes ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Phase 2 Trial ◽

Line Chemotherapy

Download Full-text

P-407 A multicenter phase 2 trial of neo-adjuvant pemetrexed pluscisplatin followed by extrapleural pneumonectomy (EPP) and radiation (RT) for malignant pleural mesothelioma (MPM)

Lung Cancer ◽

10.1016/s0169-5002(05)80900-6 ◽

2005 ◽

Vol 49 ◽

pp. S222 ◽

Author(s):

L. Krug ◽

H. Pass ◽

V. Rusch ◽

D. Sugarbaker ◽

K. Rosenzweig ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Extrapleural Pneumonectomy ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase

Download Full-text

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30765-4 ◽

2019 ◽

Vol 20 (2) ◽

pp. 239-253 ◽

Author(s):

Arnaud Scherpereel ◽

Julien Mazieres ◽

Laurent Greillier ◽

Sylvie Lantuejoul ◽

Pascal Dô ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Download Full-text

Faculty Opinions recommendation of Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734891032.793555989 ◽

2019 ◽

Author(s):

Tariq Sethi ◽

Claire Rooney

Keyword(s):

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Download Full-text

Randomized Phase 2 Trial of Adjuvant WT-1 Analog Peptide Vaccine in Patients with Malignant Pleural Mesothelioma after Completion of Multimodality Therapy

10.21236/ada554071 ◽

2011 ◽

Author(s):

Lee M. Krug

Keyword(s):

Malignant Pleural Mesothelioma ◽

Peptide Vaccine ◽

Multimodality Therapy ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Phase 2 Trial ◽

Analog Peptide ◽

Randomized Phase 2

Download Full-text

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00208-9 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1651-1658 ◽

Author(s):

Rolf A Stahel ◽

Oliver Riesterer ◽

Alexandros Xyrafas ◽

Isabelle Opitz ◽

Michael Beyeler ◽

...

Keyword(s):

Neoadjuvant Chemotherapy ◽

Malignant Pleural Mesothelioma ◽

Extrapleural Pneumonectomy ◽

Pleural Mesothelioma ◽

Phase 2 ◽

Multicentre Phase ◽

Download Full-text

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00404-6 ◽

2021 ◽

Author(s):

Carmine Pinto ◽

Paolo Andrea Zucali ◽

Maria Pagano ◽

Federica Grosso ◽

Giulia Pasello ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Pleural Mesothelioma ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

Download Full-text